MAIA Financial Statements From 2010 to 2024
| MAIA Stock | USD 2.09 0.01 0.48% |
Check MAIA Biotechnology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among MAIA Biotechnology's main balance sheet or income statement drivers, such as , as well as many indicators such as . MAIA financial statements analysis is a perfect complement when working with MAIA Biotechnology Valuation or Volatility modules.
MAIA |
MAIA Biotechnology Company Return On Asset Analysis
MAIA Biotechnology's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current MAIA Biotechnology Return On Asset | -1.07 |
Most of MAIA Biotechnology's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, MAIA Biotechnology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Based on the latest financial disclosure, MAIA Biotechnology has a Return On Asset of -1.0711. This is 87.76% lower than that of the Biotechnology sector and 95.46% lower than that of the Health Care industry. The return on asset for all United States stocks is notably higher than that of the company.
MAIA Biotechnology Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining MAIA Biotechnology's current stock value. Our valuation model uses many indicators to compare MAIA Biotechnology value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across MAIA Biotechnology competition to find correlations between indicators driving MAIA Biotechnology's intrinsic value. More Info.MAIA Biotechnology is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the MAIA Biotechnology's earnings, one of the primary drivers of an investment's value.About MAIA Biotechnology Financial Statements
MAIA Biotechnology stakeholders use historical fundamental indicators, such as MAIA Biotechnology's revenue or net income, to determine how well the company is positioned to perform in the future. Although MAIA Biotechnology investors may analyze each financial statement separately, they are all interrelated. For example, changes in MAIA Biotechnology's assets and liabilities are reflected in the revenues and expenses on MAIA Biotechnology's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in MAIA Biotechnology. Please read more on our technical analysis and fundamental analysis pages.
MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer. The company was founded in 2018 and is headquartered in Chicago, Illinois. Maia Biotechnology operates under Biotechnology classification in the United States and is traded on AMEX Exchange. It employs 9 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether MAIA Biotechnology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of MAIA Biotechnology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Maia Biotechnology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Maia Biotechnology Stock:Check out the analysis of MAIA Biotechnology Correlation against competitors. For information on how to trade MAIA Stock refer to our How to Trade MAIA Stock guide.You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of MAIA Biotechnology. If investors know MAIA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about MAIA Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of MAIA Biotechnology is measured differently than its book value, which is the value of MAIA that is recorded on the company's balance sheet. Investors also form their own opinion of MAIA Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is MAIA Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because MAIA Biotechnology's market value can be influenced by many factors that don't directly affect MAIA Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between MAIA Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if MAIA Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, MAIA Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.